A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults with Elevated Lp(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event (ACCLAIM-CTA)
Principal Investigator
Rafail Kotronias
Contact us
Email: cvm_nurses@cardiov.ox.ac.uk
IRAS number
1014051